Search
Trihexyphenidyl
go.drugbank.com/drugs/DB00376ApprovedInvestigational[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. … Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.
Rebamipide
go.drugbank.com/drugs/DB11656ApprovedInvestigationalRebamipide has been investigated for the treatment of Stomach Ulcer, Keratoconjunctivitis Sicca, and Gastric Adenoma and Early Gastric Cancer.
Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)Pegulicianine
go.drugbank.com/drugs/DB18731ApprovedInvestigational[L50537] Pegulicianine (under the brand name Lumisight) was approved for use by the FDA in April 2024.[L50537,L50547] It received Fast Track and priority review for this indication.[L50547] … Pegulicianine is an optical imaging agent indicated for fluorescence imaging in patients with breast cancer.
Categories: Compounds used in a research, industrial, or household settingBafilomycin A1
go.drugbank.com/drugs/DB06733ExperimentalThese compounds all appear in the same fermentation and have similar biological activity. Bafilomycins are specific inhibitors of vacuolar-type H+-ATPase. (V-ATPase).
Obeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigational[A192786] Obeticholic acid is a farnesoid-X receptor (FXR) agonist used to treat this condition, possibly allowing for increased survival. … [L34650] Obeticholic acid is currently being considered for FDA approval to treat fibrosis caused by non-alcoholic liver steatohepatitis (NASH).
Bordetella pertussis fimbriae 2/3 antigen
go.drugbank.com/drugs/DB10790ApprovedInvestigationalBordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct
Mixtures: , Suspension for Injection, ADACEL SUSPENSION FOR INJECTIONSimeprevir
go.drugbank.com/drugs/DB06290ApprovedWithdrawnor second-line threapies for treatment-naïve patients as adjunct to sofosbuvir treatment for genotype 1 or PEG-Interferon/ribavirin combination therapy for genotype 1 or 4. … According to 2017 American Association for the Study of Liver Diseases (AASLD) and 2015 consensus guidelines from the Canadian Association for the Study of the Liver (CASL), simeprevir can be used as first-line
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseCenegermin
go.drugbank.com/drugs/DB13926ApprovedInvestigationalIt received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. … Cenegermin also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases.
Human papillomavirus type 31 L1 capsid protein antigen
go.drugbank.com/drugs/DB10310ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 31. … Human papillomavirus type 31 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection.
Mixtures: GARDASIL 9 SUSPENSION FOR INJECTIONPirtobrutinib
go.drugbank.com/drugs/DB17472ApprovedInvestigational[L44863,L44873] In December 2025, pirtobrutinib received traditional FDA approval for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously … [A256788] In January 2023, the use of pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy was approved under the FDA's Accelerated